Duchenne muscular dystrophy (DMD) is a neuromuscular disease characterized by rapidly progressive muscle weakness and wasting due to degeneration of skeletal and cardiac muscle.
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 15, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 15, 2026
Actionable guidance for navigating care for Duchenne muscular dystrophy
To effectively navigate care for Duchenne muscular dystrophy (DMD), consider seeking specialists such as a pediatric neurologist with neuromuscular expertise, a cardiologist for cardiac monitoring, and a pulmonologist for respiratory health. You may also benefit from physical and occupational therapy. Connect with patient organizations like Parent Project Muscular Dystrophy (https://www.parentprojectmd.org) and Cureduchenne (https://cureduchenne.org) for resources and support. Additionally, explore the Duchenne Registry (https://duchenneregistry.org) for participation in research. For genetic counseling, visit findageneticcounselor.com to locate a qualified professional who can assist in understanding the implications of the DMD gene variant for your family.
Consider asking your healthcare providers these condition-specific questions
Connect with organizations supporting the Duchenne muscular dystrophy community
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Feb 15, 2026
Parent Project Muscular Dystrophy's mission is to end Duchenne muscular dystrophy.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
5 peer-reviewed sources from PubMed
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning Duchenne muscular dystrophy
Updated Feb 17, 2026
The 'Omirge Sen' Foundation launched a video campaign for Rare Disease Day 2026 to raise awareness about hereditary neuromuscular diseases, including Duchenne muscular dystrophy and spinal muscular atrophy. This initiative highlights the stories of affected families and aims to support those impacted by these conditions.
The 'Omirge Sen' Foundation launched a video for Rare Disease Day 2026 to raise awareness about hereditary neuromuscular diseases, including Duchenne muscular dystrophy and spinal muscular atrophy. This initiative highlights the stories of families affected by these conditions.
A recent study published in PubMed details the clinical diagnosis and genetic analysis of a rare case involving both Duchenne muscular dystrophy and spinal muscular atrophy. This research contributes to the understanding of these conditions and may inform future diagnostic and therapeutic approaches.
Avidity Biosciences, REGENXBIO, and Capricor Therapeutics are preparing key regulatory applications for Duchenne muscular dystrophy treatments this year, signaling a potential shift in the DMD pipeline following Sarepta's recent challenges. CureDuchenne's CSO Michael Kelly notes a growing momentum in the field.
The EU-funded DREAMS project, now including University College London, aims to accelerate the discovery of treatments for rare neuromuscular disorders. By leveraging AI-based drug discovery and advanced screening methods, the project targets five specific diseases, including Duchenne muscular dystrophy and centronuclear myopathy.